(Q40528278)

21 September 2017

title

Ebola and Marburg virus-like particles activate human myeloid dendritic cells (English)

1 reference

21 September 2017

main subject

Orthoebolavirus zairense

0 references

0 references

1 reference

7

Sina Bavari

1 reference

21 September 2017

4

Gordon Ruthel

1 reference

21 September 2017

6

M Javad Aman

1 reference

21 September 2017

1

Catharine M Bosio

1 reference

21 September 2017

3

Kelly L Warfield

1 reference

21 September 2017

5

Mansour Mohamadzadeh

1 reference

21 September 2017

Brian D Moore

2

1 reference

21 September 2017

language of work or name

English

0 references

publication date

1 September 2004

1 reference

21 September 2017

1 reference

21 September 2017

volume

326

1 reference

21 September 2017

issue

2

1 reference

21 September 2017

page(s)

280-287

1 reference

The Ebola virus VP35 protein functions as a type I IFN antagonist.

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.05.025

The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.05.025

Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.05.025

Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.05.025

CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.05.025

Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.05.025

Vaccine research efforts for filoviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.05.025

Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.05.025

Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.05.025

Ebola virus VP40-induced particle formation and association with the lipid bilayer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.05.025

Emerging viral infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.05.025

Papillomavirus-like particles induce acute activation of dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.05.025

Dendritic cells: immune regulators in health and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.05.025

Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.05.025

Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.05.025

A recombinant human papillomavirus (HPV) type 16 L1-vaccinia virus murine challenge model demonstrates cell-mediated immunity against HPV virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.05.025

Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.05.025

Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.05.025

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.05.025

Generation of Marburg virus-like particles by co-expression of glycoprotein and matrix protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.05.025

An Ebola epidemic simmers in Africa: in remote region, outbreak shows staying power

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.05.025

Vesicular release of ebola virus matrix protein VP40.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.05.025

Ebola virus-like particles protect from lethal Ebola virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.05.025

Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.05.025

Ape populations decimated by hunting and Ebola virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.05.025

Epitopes involved in antibody-mediated protection from Ebola virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.05.025

Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.05.025

Marburg and Ebola viruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.05.025

Comparison of the transcription and replication strategies of marburg virus and Ebola virus by using artificial replication systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.05.025

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VIROL.2004.05.025

1 reference

21 September 2017

1 reference